Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | PREP | P48147 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22926902 | 0.89 | LMNA (0.41) | LMNACYP2C9PREPTDP1 | |
| SCHEMBL20639384 | 0.80 | TDP1 (0.39) | LMNACYP2C9PREPTDP1 | |
| SCHEMBL8278523 | 0.80 | LMNA (0.34) | LMNACYP2C9PREPTDP1 | |
| SCHEMBL18943173 | 0.80 | TDP1 (0.39) | LMNACYP2C9PREPTDP1 | |
| SCHEMBL8278611 | 0.74 | CHRM2 (0.38) | LMNACYP2C9PREP | |
| SCHEMBL13245325 | 0.74 | CHRM2 (0.34) | LMNACYP2C9PREP | |
| SCHEMBL15451675 | 0.72 | CHRM2 (0.33) | CYP2C9PREP | |
| SCHEMBL15451680 | 0.71 | LMNA (0.34) | LMNACYP2C9 | |
| SCHEMBL8277176 | 0.70 | LMNA (0.43) | LMNACYP2C9PREPTDP1 | |
| SCHEMBL22926910 | 0.70 | LMNA (0.43) | LMNACYP2C9PREPTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11325921-B2 | Optically active crosslinked cyclic secondary amine derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-05-10 | — | — | US | disclosed |
| US-20210024547-A1 | OPTICALLY ACTIVE CROSSLINKED CYCLIC SECONDARY AMINE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2021-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210024547-A1 | OPTICALLY ACTIVE CROSSLINKED CYCLIC SECONDARY AMINE DERIVATIVE | MLLT3, MEN1, MLLT1 | LMNA 693/4885CYP2C9 2631/4885PREP 4524/4885 |
| US-11325921-B2 | Optically active crosslinked cyclic secondary amine derivative | MLLT3, MEN1, MLLT1 | LMNA 693/4885CYP2C9 2631/4885PREP 4524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.